ImmunityBio, Inc. IBRX Net gains (losses) on investments
Net gains (losses) on investments at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s net gains (losses) on investments?
- ImmunityBio, Inc. (IBRX) reported net gains (losses) on investments of -$180K in Q1 2026.
- How has ImmunityBio, Inc.'s net gains (losses) on investments changed year-over-year?
- ImmunityBio, Inc.'s net gains (losses) on investments decreased by 1536.4% year-over-year, from -$11K to -$180K.
- What is the long-term trend for ImmunityBio, Inc.'s net gains (losses) on investments?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s net gains (losses) on investments has grown at a -100.0% compound annual growth rate (CAGR), from -$4.62M to $0.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.